Global Cancer Technology Receives SEC Notice of Qualification for Reg A+ Tier II Registration
Company Plans to Raise $9 Million USD with Proceeds to Fund New COVID Treatment Using Nanoparticles, UV Light and Chest X-ray
San Diego, CA, December 4, 2020 – Global Cancer Technology, Inc. announced today that the company has received notice from the SEC acknowledging the company is qualified to proceed with its effort to raise approximately $9 Million under a Tier II Reg A+ offering. “In this public offering, the company is offering up to 3,500,000 shares of our common stock at $2.00 per share and our selling shareholders are offering 1,043,788 shares of our common stock at $2.00 per share until our shares are quoted on the NASDAQ market,” said Mr. John Clark, chairman and CEO of Global Cancer Technology, Inc. Mr. Clark went on to say that, “The Company intends to use a portion of its net proceeds to develop and commercialize its recently licensed technology for a new COVID breakthrough treatment using nanoparticles, UV light and chest x-rays. Milan Makale, PhD and Company CTO commented, “With our technology licensed from the UCSD Medical System, we can coat nanoparticles with protein molecules that will bind to COVID in the respiratory track. We send our particles to the respiratory tract through ventilators or inhalers, then apply external radiation (chest x-ray), which causes our nanoparticles to give off UV light, killing the bound COVID virus.” Global Cancer Technology, Inc. has engaged Dalmore Group, LLC, member FINRA/SIPC to act as the broker-dealer of record in connection with this offering. For additional information, please visit: www.globalcancertechnology.com.